Comparison criteria: Difference between revisions

From Opasnet
Jump to navigation Jump to search
(→‎See also: GSK comments added)
(resolution updated to main page)
Line 17: Line 17:
== Answer ==
== Answer ==


The tentative proposal is that the comparison of vaccine products will be based on price and assessed benefits. Benefits are quantified as the expected decrease in invasive pneumococcal disease incidence due to vaccination. This tentative proposal is the basis for the conversation beginning in the summer of 2014.  
The proposal is that the comparison of vaccine products will be based on price, assessed benefits, and technical criteria. Benefits are quantified as the expected decrease in invasive pneumococcal disease incidence due to vaccination. However, if there were enough reliable data, also pneumonia and other respiratory endpoints should be considered.


== Rationale ==  
== Rationale ==  


According to the public procurement law, comparison criteria related to differences in the products can be applied  if (1) the differences are clearly demonstrated and (2) the differences can be quantified in terms of increased or decreased benefits. In particular, technical differences typically fall outside of this realm. So far no credible differences in safety among the currently licensed pneumococcal conjugate vaccines have been demonstrated.
According to the public procurement law, comparison criteria related to differences in the products can be applied  if (1) the differences are clearly demonstrated and (2) the differences can be quantified in terms of increased or decreased benefits. In particular, technical differences typically fall outside of this realm. So far no credible differences in safety among the currently licensed pneumococcal conjugate vaccines have been demonstrated.
<br>
 
<br>
To assess the health benefits of vaccination, the following items needs to be known or assessed:
To assess the health benefits of vaccination, the following items needs to be known or assessed:
* pneumococcal serotypes included in the vaccine
* pneumococcal serotypes included in the vaccine
* decrease in the pneumococcal disease incidence due to vaccination
* decrease in the pneumococcal disease incidences due to vaccination
* the potential protection of the vaccine against disease caused by the bacterium ''Haemophilus influenzae''
* the potential protection of the vaccine against disease caused by the bacterium ''Haemophilus influenzae''
<br>


The tentative assumption is that the use of either the 10-valent (PCV10) or 13-valent (PCV13) pneumococcal conjugate vaccine (PCV) in the childhood immunization programme significantly reduces the disease incidence attributable to the serotypes included in the vaccine and that this protection extends to the population at large. This assumption may be modified so that the vaccine also reduces disease incidence caused by certain serotypes not included in the vaccine (due to cross-protection). The predicted reduction in invasive pneumococcal disease due to vaccination is calculated using an epidemiological model.  
The tentative assumption is that the use of either the 10-valent (PCV10) or 13-valent (PCV13) pneumococcal conjugate vaccine (PCV) in the childhood immunization programme significantly reduces the disease incidence attributable to the serotypes included in the vaccine and that this protection extends to the population at large. This assumption may be modified so that the vaccine also reduces disease incidence caused by certain serotypes not included in the vaccine (due to cross-protection). The predicted reduction in invasive pneumococcal disease due to vaccination is calculated using an epidemiological model.  


<br>
The vaccine-preventable pneumococcal disease incidence used in the model is assumed to correspond to  
The vaccine-preventable pneumococcal disease incidence used in the model is assumed to correspond to  
proven (blood culture-positive) invasive pneumococcal disease.
proven (blood culture-positive) invasive pneumococcal disease.
In view of recent knowledge (Palmu et al, 2014, in press) and  
In view of recent knowledge <ref>(Palmu et al, 2014, in press)</ref> and  
if deemed feasible,  also estimates
if deemed feasible,  also estimates
of non-laboratory-confirmed IPD among children under 5 years of age can be included.  
of non-laboratory-confirmed IPD among children under 5 years of age can be included.  
For other pneumococcal disease endpoints, reliable estimates of the vaccine-preventable disease incidences are not available.
For other pneumococcal disease endpoints, reliable estimates of the vaccine-preventable disease incidences are not available.
Therefore, criteria or endpoints that should be considered are a) price, b) invasive pneumococcal disease, and c) technical criteria. However, if there were enough reliable data, also pneumonia and other respiratory endpoints should be included.{{reslink|Health endpoints to consider}}


== See also ==


{{pneumococcal vaccine}}


== See also ==
== References ==


{{pneumococcal vaccine}}
<references/>


== Related files ==
== Related files ==

Revision as of 08:27, 8 September 2014

Progression class
In Opasnet many pages being worked on and are in different classes of progression. Thus the information on those pages should be regarded with consideration. The progression class of this page has been assessed:
This page is a full draft
This page has been written through once, so all important content is already where it should be. However, the content has not been thoroughly checked yet, and for example important references might still be missing.
 This page needs a curator. Learn more about curating Opasnet pages.

Question

Which comparison criteria should be used in the tendering process for the selection of a pneumococcal conjugate vaccine within the national vaccination programme for children in Finland? The tendering process will be initiated during the autumn of 2014.

  • Possible comparison criteria include price, benefits, safety and technical properties.
    • Price refers to the bargaining price of the vaccine.
    • Benefits refer to the decrease in disease burden caused by large scale use of the vaccine. As a result health care costs decrease and the quality of life attributed to improved health increases.
    • Safety
    • Technical properties
  • The benefits of the pneumococcal conjugate vaccine are quantified by the decrease of disease forms caused by pneumococcus and the bacterium Haemophilus influenzae.
  • The benefits are assessed in the entire Finnish population.

Answer

The proposal is that the comparison of vaccine products will be based on price, assessed benefits, and technical criteria. Benefits are quantified as the expected decrease in invasive pneumococcal disease incidence due to vaccination. However, if there were enough reliable data, also pneumonia and other respiratory endpoints should be considered.

Rationale

According to the public procurement law, comparison criteria related to differences in the products can be applied if (1) the differences are clearly demonstrated and (2) the differences can be quantified in terms of increased or decreased benefits. In particular, technical differences typically fall outside of this realm. So far no credible differences in safety among the currently licensed pneumococcal conjugate vaccines have been demonstrated.

To assess the health benefits of vaccination, the following items needs to be known or assessed:

  • pneumococcal serotypes included in the vaccine
  • decrease in the pneumococcal disease incidences due to vaccination
  • the potential protection of the vaccine against disease caused by the bacterium Haemophilus influenzae

The tentative assumption is that the use of either the 10-valent (PCV10) or 13-valent (PCV13) pneumococcal conjugate vaccine (PCV) in the childhood immunization programme significantly reduces the disease incidence attributable to the serotypes included in the vaccine and that this protection extends to the population at large. This assumption may be modified so that the vaccine also reduces disease incidence caused by certain serotypes not included in the vaccine (due to cross-protection). The predicted reduction in invasive pneumococcal disease due to vaccination is calculated using an epidemiological model.

The vaccine-preventable pneumococcal disease incidence used in the model is assumed to correspond to proven (blood culture-positive) invasive pneumococcal disease. In view of recent knowledge [1] and if deemed feasible, also estimates of non-laboratory-confirmed IPD among children under 5 years of age can be included. For other pneumococcal disease endpoints, reliable estimates of the vaccine-preventable disease incidences are not available. Therefore, criteria or endpoints that should be considered are a) price, b) invasive pneumococcal disease, and c) technical criteria. However, if there were enough reliable data, also pneumonia and other respiratory endpoints should be included.R↻

See also

Tendering process for pneumococcal conjugate vaccine
Parts of the assessment

Comparison criteria for vaccine   · Epidemiological modelling   · Economic evaluation

Background information

Sensitivity analysis · Replacement   · Pneumococcal vaccine products   · Finnish vaccination schedule   · Selected recent publications

Help for discussion and wiki editing

Pages in Finnish

Pneumokokkirokotteen hankinta  · Rokotteen vertailuperusteet · Epidemiologinen malli · Taloudellinen arviointi · Pneumokokkirokotteen turvallisuus

Work scheduling · Monitoring the effectiveness of the pneumococcal conjugate vaccine · Glossary of vaccine terminology


References

  1. ↑ (Palmu et al, 2014, in press)

Related files

Comment the content


Retrieved from "https://en.opasnet.org/index.php?title=Comparison_criteria&oldid=33640"